On September 19, Pfizer announced that the European Commission (EC) has approved LITFULO™ (ritlecitinib) for marketing, to treat adolescents aged 12 years and above and adult patients with severe alopecia areata.
Pfizer Announces European Commission Approval of LITFULO™ (ritlecitinib) for Severe Alopecia Areata in Patients Aged 12 and Older
Sep 19, 2023 15:16
CST Updated
15:16
Pfizer
Pharmaceutical R&D Developer